Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.
Govoni M, Bortoluzzi A, Lo Monaco A, Adami S, Addimanda O, Caimmi C, De Vita S, Ferri C, Manfredi A, Orsolini G, Possemato N, Quartuccio L, Salvarani C, Zabotti A, Rossini M. Govoni M, et al. Among authors: zabotti a. Adv Ther. 2014 Aug;31(8):780-802. doi: 10.1007/s12325-014-0142-8. Epub 2014 Aug 12. Adv Ther. 2014. PMID: 25112460 Review.
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. De Vita S, et al. Among authors: zabotti a. Arthritis Rheum. 2012 Mar;64(3):843-53. doi: 10.1002/art.34331. Arthritis Rheum. 2012. PMID: 22147661 Free article. Clinical Trial.
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. Fabris M, et al. Among authors: zabotti a. Arthritis Rheum. 2013 Jan;65(1):88-97. doi: 10.1002/art.37707. Arthritis Rheum. 2013. PMID: 23001900 Free article.
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S. Quartuccio L, et al. Among authors: zabotti a. Ann Rheum Dis. 2014 Apr;73(4):716-21. doi: 10.1136/annrheumdis-2012-202435. Epub 2013 Mar 16. Ann Rheum Dis. 2014. PMID: 23505228
118 results